head_banner

About Zeesan

Company Overview in Numbers

  • ISO
  • m Certificated Clean Factory
  • Founded in
  • CE-IVDD
  • Supplies to Over Countries
  • CE-IVDR
  • Mission

    Advance molecular diagnostic tools to unlock the valuable medical insights encoded in the basic building blocks of human body – nucleic acids, making a difference in improving early detection of diseases, precise treatment and prognosis monitoring.

    pic_34

    Vision

    We are ambitious to bring our unique and reliable solutions to clinical healthcare from all over the world, working towards a future where everyone has access to timely diagnosis for prevention and life-changing treatment.

    vision

    Our Technology

  • Multicolor

    multiple probes

  • Melting

    melt curve analysis

  • Curve

    each mutation has its Tm

  • Analysis

    single step like
    real-time PCR

  • *MMCA-based multplex PCR platform has been granted several International invention patents.

    Patented Multicolor Melting Curve Analysis (MMCA®) overcomes the limitations of conventional RT-PCR in terms of the maximum number of detectable targets (usually between 2-5, depending on the number of fluorescence channels) in one tube.

    *Huang et al, PNAS, 2022

    MMCA 2D Label = Fluorescence Channels + Melting Curve

    12 targets/channel X 6 fluorescence channels

    With MMCA®, up to 72 targets can be detected simultaneously in one tube. As short as 40 minutes to result

    Our History

  • 2010

    2010

    ● Xiamen Zeesan Biotech Co., Ltd. was established.
    ● Zeesan obtained the Medical Device Manufacturing License issued by National Medical Products Administration (NMPA), China.

  • 2011

    2011

    ● Zeesan obtained the Medical Device Distribution License issued by NMPA, China.


  • 2012

    2012

    ● Zeesan was awarded -The National High-Tech Enterprise in China -Xiamen Double-Hundred Innovative Enterprises -China High-Potential Startup Company.

  • 2013

    2013

    ● Zeesan was certified to ISO 9001 standard and ISO 13485 medical device development and manufacturing standards.
    ● Two drug-resistant TB kits got NMPA approval.
    ● Saliva sample collection kits were launched.

  • 2014

    2014

    ● Zeesan was officially listed in China's New Third Board.
    ● Non-deletional α-thalassemia detection kit got NMPA approval.

  • 2015

    2015

    ● Zeesan was awarded (Xiaman Innovative Enterprise, Xiamen Incubator Successful Enterprise).
    ● One nucleic acid extractor was launched.

  • 2016

    2016

    ● Zeesan's drug resistance TB test was selected as "2016 China Top10 Medical Science and Technology News".
    ● The development of Zeesan's drug resistance TB tests were included in national "12th Five-Year" major projects.
    ● Three drug resistance TB test kits got NMPA approval.

  • 2017

    2017

    ● The development of Zeesan's drug resistance TB tests were included in national "13th Five-Year" major projects.
    ● Deletional α-thalassemia detection kit got NMPA approval.
    ● Zeesan was awarded first prize of Xiamen invention patents.

  • 2018

    2018

    ● Lab-Aid 824s and Lab-Aid 808 Nucleic Acid Extraction System were launched.
    ● Lab-Aid 824s DNA Extraction Kit was launched.
    ● HPV genotyping kits got NMPA approval.
    ● Leukemia fusion gene screening kit was launched.

  • 2019

    2019

    ● Zeesan was awarded “Xiamen Fast-growing SME”.
    ● Lab-Aid 960 Nucleic Acid Extraction System was launched.

  • 2020

    2020

    ● 36 CE-certified products were approved to export to outside China, including Asia, Europe and Americas regions.
    ● Zeesan was awarded "Specialized and Sophisticated SME".

  • 2021

    2021

    ● Sanity 2.0 System got NMPA approval.
    ● Zeesan Medical Laboratory was established.
    ● The founder Prof. Li Qingge was awarded "Xiamen Top10 Influential Person in Strategic Emerging Industries".

  • 2022

    2022

    ● Zeesan was awarded "Fujian Nucleic Acid Detection Research Center".
    ● Zeesan was awarded "Xiamen Key Laboratory for Multi-target and Automated Nucleic Acid Detection".
    ● Mycobacteria identification kit got NMPA approval.

  • 2023

    2023

    ● The NMPA Class III registration for MDR-TB test kit is in progress.
    ● Zeesan is actively expanding overseas markets, products completed registration in Indonesia (3 products), Malaysia (3 products), Thailand (12 products), the registration in other countries are ongoing.

  • Our Global Partners

    Our-Global-Partners1

    Interested to Know More about Our Solution to Molecular Diagnostics?

    Let’s talk